Targeted Therapies
Understanding the challenges of precision medicine
Targeted therapies and niche patient populations all require focus, deep therapeutic understanding and high levels of experience – and so should your study team.
Our Targeted Therapies team concentrates exclusively on new approaches to precision medicine for solid tumors, including combination immunotherapies, biomarker-driven therapies, biosimilars, antibody drug conjugates, other small molecules and complex study designs across all phases.
Our Depth of Experience
In the last 5 years
Our solid tumor experience totaled
366
studies
366
studies
366
studies
During those 5 years
Our Targeted therapies experience in solid tumors included
150
studies
150
studies
Tailoring mechanisms
of action (MoA) to
each patient, phase
by phase
Engaging with the right sites and patients from day one
When it comes to precision medicine, the ability to connect with patients through investigative sites ranks as highly as medical and operational expertise.
Our therapeutic alignment means that we are able to engage with focus, passion and peer-to-peer scientific expertise to develop deep relationships with key opinion leaders, investigators and sites. We are the only CRO to field dedicated Research Science Liaisons (MSLs) for this purpose – helping you meet your recruitment targets faster, no matter how complex the trial.
Whether motivated by the personal journey of a cancer patient or the challenge and rigor of cancer clinical research, at Syneos Health we are passionate about collaborating for a cure.
A fully integrated, insights driven product development methodology, Syneos One provides a unique combination of asset strategy and execution to maximize value from early concept through commercialization.
Novel and Emerging Therapies
Read about the three areas our Novel and Emerging Therapies group specialize in to provide unparalleled depth of expertise.
Immuno-Oncology
We were early pioneers in immunotherapy. See how our clinical professionals continue to support new approaches across all phases.
Early Phase Oncology
Whatever the size of your early phase oncology project and wherever you are in the world, we have it covered.
Cross-functional collaboration is our hallmark
A fully integrated, insights driven product development methodology, Syneos One provides a unique combination of asset strategy and execution to maximize value from early concept through commercialization.
Further specialized expertise is available from our Consortia in a number of key strategic areas, including Cell and Gene Therapy, Rare Disease and Pediatrics.
Our Consortia are powered by our end-to-end business model, where clinical and commercial expertise and insights combine to accelerate new therapies to market.
Learn more about how our Consortia model helps shorten the distance from lab to life.
